Update on the ongoing receivership procedure – 04/11/2025

A takeover bid within the context of a sales plan has been received by the judiciary administrator

Paris, November 4, 2025 – 5:30 pm CET

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure.

Update on the ongoing receivership procedure

On October 15, 2025, CARMAT had announced a new call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025. The deadline set for submitting bids was November 3, 2025.

By that date, one takeover bid within the context of a sales plan[1] (the “Bid”), was received by the judiciary administrator. The Bid was submitted by “CARMAT SAS”, a simplified joint stock company[2] set-up for the purpose of the potential Bid, share capital of which is currently held by LOHAS S.à.r.l, a company controlled by Mr. Pierre Bastid (the “Buyer”), who is CARMAT’s Chairman of the Board and holds about 17% of CARMAT shares.

The Bid, which can still be adjusted until November 20, 2025, should be assessed by the Versailles Economic Court[3] (the “Court”) at a hearing scheduled on November 25, 2925.

The Company draws attention to the fact that there is no guarantee at this stage that the Bid will be successful (i.e. that the conditions precedent will be met and that the Court will ultimately decide a sales plan based on this Bid). If the Bid is not successful, it is highly probable that CARMAT will be liquidated (under the rules applicable to judicial liquidations) and its operations will stop. In such a case, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

Conversely, if the Bid is ultimately validated by the Court, part or all of CARMAT’s operations will continue as part of another legal entity. However, in that case, CARMAT will also be liquidated, and given CARMAT’s level of liabilities, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

It is reminded that, should it be liquidated, the Company would request the delisting of its shares from Euronext.

Next steps

Trading of CARMAT shares (ISIN code: FR0010907956, Ticker: ALCAR) remains suspended.

Press releases will be issued regularly as the Company’s situation evolves and the proceedings progress.

Until the next hearing scheduled on November 25, 2025, with a view to contain its cash burn, CARMAT will continue to limit its operations to the minimum, focusing in first instance on support to patients currently benefitting from Aeson®.

In any case, the support to these patients is CARMAT’s priority, so the Company endeavors to ensure that this continuous support is maintained even if CARMAT is liquidated and its operations cease.

[1] « Offre de reprise en plan de cession ».

[2] SAS : « Société par Actions Simplifiée »

[3] Tribunal des Activités Economiques de Versailles.

CARMAT announces postponing the publication of its 2025 interim financial report (six months ended June 30, 2025)

Paris, October 29, 2025 – 7:30 am (CET)    

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces postponing the publication of its 2025 interim financial report (six months ended June 30, 2025).

Reminder on the ongoing receivership procedure

CARMAT has been under receivership procedure since July 1, 2025.

During a hearing on September 30, 2025, the Versailles Economic Court[1] (the “Court”) had acknowledged that the only take-over-bid within the context of a sales plan which had been received, had lapsed. Given this, the judiciary administrator had submitted to the Court a request aiming at converting the receivership into a liquidation procedure, which was reviewed by the Court during a hearing held on October 14, 2025.

During this hearing, the Court decided to postpone the review of this request aiming at converting the receivership into a liquidation procedure, until November 25, 2025.

Consequently, the on-going receivership procedure continues and a new bidding process was initiated by the judiciary administrator. New bids (the “New Bids”) can be submitted until November 3, 2025. If any, they should be reviewed by the Court during a hearing scheduled on Novembre 25, 2025.

The Company draws attention to the fact that there is no guarantee at this stage that New Bids will be submitted and then validated by the Court following the hearing scheduled on November 25, 2025. If no New Bid is successful, it is almost certain that CARMAT will be liquidated (under the rules applicable to judicial liquidations) and its operations will stop. In such a case, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

Conversely, if a New Bid is ultimately validated by the Court, all or part of CARMAT’s operations could continue either within CARMAT or as part of another legal entity. If operations continue as part of another legal entity, CARMAT will be liquidated (under the rules applicable to judicial liquidations), and given CARMAT’s level of liabilities, it is highly probable that also in that case, its shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

It is reminded that should CARMAT be liquidated, the Company would request the delisting of its shares from Euronext.

Postponement of the publication of the 2025 interim financial report (6 months ended June 30, 2025)

In this context, the Board of directors considered, following its meeting held on October 28, 2025, that it was not in position to sign-off[2] the 2025 interim financial report, given the very high degree of uncertainty regarding the future of the Company, which did not allow them, at this stage, to assess whether applying the going concern basis is appropriate or not.

As a result of this, the publication of the 2025 interim financial report (six months ended June 30, 2025), originally scheduled on October 31, 2025, is postponed to a later date. Any future decision about this matter will depend on the evolution of the Company’s situation.

Trading of CARMAT shares (ISIN code: FR0010907956, Ticker: ALCAR) remains suspended.

Another press release will be issued by the Company after the deadline set for the submission of the bids, namely November 3, 2025.

In the meantime, in order to contain its cash-burn, CARMAT limits its operations to the minimum, focusing on support to patients currently benefitting from Aeson®.

In any case, the support to these patients is CARMAT’s priority, so the Company endeavors for this continuous support to get provided even if CARMAT is liquidated and its operations stop

[1] Tribunal des Activités Economiques de Versailles.

[2] « arrêter les comptes ».

Paris, October 1, 2025 – 7:30 am (CEST)    

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure.

Update on the ongoing receivership procedure

Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, by the Versailles Economic Court[1] (the “Court”), the judiciary administrator had received, on July 31, 2025, one takeover bid within the context of a sales plan (the “Bid”)[2], submitted by HOUGOU, the family office of Mr Pierre Bastid (the “Buyer”), who is CARMAT’s chairman of the board and holds about 17% of CARMAT shares.

During a hearing held on August 19, 2025, the Court had granted the Buyer more time to finalize his Bid and lift the conditions precedent with a view to then get the Bid assessed by the Court during a hearing scheduled on September 30, 2025.

During the hearing on September 30, 2025, the Court acknowledged that the Bid had lapsed, given the fact that the Buyer had not been able to lift all conditions precedent, notably the one relating to securing the financing required for the takeover bid.

The judiciary administrator has thus submitted to the Court a request aiming at converting the receivership into a liquidation procedure, which should be reviewed by the Court during a hearing scheduled on October 14, 2025.

At this stage, it is thus now extremely probable that the Court will, on October 14, 2025, decide the liquidation of the Company, which operations will then stop.

CARMAT again draws attention to the fact that in that case, given the Company’s level of liabilities, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables. The Company also reminds that a liquidation will lead to the delisting of its shares currently listed on Euronext Growth (Paris).

Next Steps

Trading of CARMAT shares (ISIN code: FR0010907956, Ticker: ALCAR) remains suspended.

Another press release will be issued by the Company once the outcome of the court hearing scheduled on October 14, 2025 is known.

In any case, the support to patients who currently benefit from its Aeson® artificial heart, is CARMAT’s priority, so the Company endeavors for this continuous support to get provided even if CARMAT is liquidated and its operations stop.

[1] Tribunal des Activités Economiques de Versailles.

^[2] « Offre de reprise en plan de cession » (in French).

Paris, September 29, 2025 – 2:00 pm (CEST)    

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure.

Update on the ongoing receivership procedure

Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, by the Versailles Economic Court[1] (the “Court”), the judiciary administrator had received, on July 31, 2025, one takeover bid within the context of a sales plan (the “Bid”)[2], submitted by HOUGOU, the family office of Mr Pierre Bastid (the “Buyer”), who is CARMAT’s chairman of the board and holds about 17% of CARMAT shares.

During a hearing held on August 19, 2025, the Court granted the Buyer more time to finalize his Bid and lift the conditions precedent with a view to then get the Bid be assessed by the Court during a hearing scheduled on September 30, 2025.

As of today, the Buyer has however not been in position to confirm his Bid given the fact that he has not managed to secure the financing required for the takeover bid.

At this stage, it is thus now extremely probable that the Bid will lapse on September 30, 2025, and that the Court will, in the very short term, decide the liquidation of the Company, which operations will then stop.

CARMAT again draws attention to the fact that in that case, given the Company’s level of liabilities, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables. The Company also reminds that a liquidation will lead to the delisting of its shares currently listed on Euronext Growth (Paris).

Next Steps

Trading of CARMAT shares (ISIN code: FR0010907956, Ticker: ALCAR) remains suspended.

Another press release will be issued by the Company once the outcome of the court hearing scheduled on September 30, 2025 is known.

In any case, the support to patients who currently benefit from its Aeson® artificial heart, is CARMAT’s priority, so the Company endeavors for this continuous support to get provided even if CARMAT is liquidated and its operations stop.

[1] Tribunal des Activités Economiques de Versailles.

^[2] « Offre de reprise en plan de cession » (in French).

Trading of CARMAT shares suspended, starting September 25, 2025, before stock market opening, ahead of the court hearing scheduled on September 30, 2025

Paris, September 24, 2025 – 6:00 pm CEST    

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting September 25, 2025, before stock market opening, ahead of the court hearing scheduled on September 30, 2025.

Update on the ongoing receivership procedure

Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, by the Versailles Economic Court[1] (the “Court”), the judiciary administrator had received, on July 31, 2025, one takeover bid within the context of a sales plan (the “Bid”)[2], submitted by HOUGOU, the family office of Mr Pierre Bastid (the “Buyer”), who is CARMAT’s chairman of the board and holds about 17% of CARMAT shares.

During the last hearing held on August 19, 2025, the Court granted the Buyer more time to finalize his Bid and lift the conditions precedent. The final Bid which must be submitted no later than September 25, 2025, will be assessed by the Court during a hearing scheduled on September 30, 2025.

It is reminded that given the provision of €1.3m in cash made by the Buyer to CARMAT[3] following the hearing held on August 19, 2025, the Company’s cash runway has been extended until early October 2025.

The Company again draws attention to the fact that there is no guarantee at this stage that the Bid will be successful i.e. that the conditions precedent will be met and that the Court will validate this Bid following the hearing scheduled on September 30, 2025. If the Bid is not successful, it is highly probable that CARMAT will be liquidated (under the rules applicable to judicial liquidations) and its operations will stop. In such a case, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

Conversely, if the Bid is ultimately validated by the Court, CARMAT’s operations will be transferred to the Buyer and will thus continue as part of another legal entity. In this scenario, CARMAT will also be liquidated (under the rules applicable to judicial liquidations) and given current terms of the Bid and CARMAT’s level of liabilities, it is highly probable that also in that case, the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

At this stage, it is thus very probable that in any case, CARMAT will be liquidated very shortly (under the rules applicable to judicial liquidations), which will lead the Company to request the delisting of its shares from Euronext.

Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR)

Ahead of the court hearing scheduled on September 30, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on September 25, 2025, before the stock market opens.

Another press release will be issued by the Company once the outcome of the court hearing is known.

In any case, even if the Company is liquidated and its operations stop, CARMAT endeavors to take the necessary steps so that continuous support to patients who currently benefit from its Aeson® artificial heart is provided.

[1] Tribunal des Activités Economiques de Versailles.

^[2] « Offre de reprise en plan de cession » (in French).

[3] These funds are not refundable and will thus be retained by CARMAT even if the Bid is not ultimately successful.

Resumption of CARMAT shares trading starting on August 21, 2025, at stock market opening

Paris, August 20, 2025 – 7:00 am CEST

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure and announces the resumption of CARMAT shares trading, starting on August 21, 2025, at stock market opening.

Update on the ongoing receivership procedure

Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, one takeover bid within the context of a sales plan (the “Bid”), had been received and could be improved until August 13, 2025 included. This Bid was discussed with the Versailles Economic Court (the “Court”) at a hearing held on August 19, 2025.

The Bid was submitted by HOUGOU, the family office of Mr Pierre Bastid (the “Buyer”), who is CARMAT’s chairman of the board and holds about 17% of CARMAT shares .

Following the hearing and upon the Buyer’s request, the Court granted him more time to finalize his Bid and lift the conditions precedent. The Bid will thus be assessed again by the Court during a hearing scheduled on September 30, 2025.

In order to enable CARMAT to fund its activities until that date and to protect creditors’ interests despite this delay, the Buyer will immediately provide €1.3m in cash to CARMAT. These funds are not refundable and will be retained by the Company even if ultimately, the Bid is not successful .

The Company again draws attention to the fact that there is no guarantee at this stage that the Bid will be successful i.e. that the conditions precedent will be met and that the Court will validate this Bid following the hearing now scheduled on September 30, 2025. If the Bid is not successful, it is highly probable that CARMAT will be liquidated (under the rules applicable to judicial liquidations) and its operations will stop. In such a case, it is highly probable that the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

Conversely, if the Bid is ultimately validated by the Court, CARMAT’s operations will be transferred to the Buyer and will continue as part of another legal entity. In this event, CARMAT will also be liquidated (under the rules applicable to judicial liquidations), and the Company draws attention to the fact that given current terms of the Bid and CARMAT’s level of liabilities, it is highly probable that also in that case, the shareholders will lose the total value of their investment, while a major part of CARMAT’s creditors will incur a very significant loss of up to the total value of their receivables.

At this stage, it is thus very probable that in any case, CARMAT will be liquidated very shortly (under the rules applicable to judicial liquidations), which will lead the Company to request the delisting of its shares from Euronext.

Resumption of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR)

CARMAT is going to ask Euronext to resume the trading of its shares starting on August 21, 2025, at stock market opening.

Next steps

Pending the next hearing scheduled on September 30, 2025, CARMAT continues to focus its activities, on one hand on supporting patients already implanted with its Aeson® artificial heart, and on the other hand, on regulatory and operational activities deemed key in view of resuming operations in the best possible way once its financial sustainability has been secured. In particular, the Company keeps suspending all new Aeson® implants, whether for commercial purpose or as part of clinical trials.

Press releases will be issued regularly as the Company’s situation evolves and the proceedings progress.

In any case, even if the Company is liquidated and its operations stop, CARMAT endeavors to take the necessary steps so that continuous support to patients who currently benefit from its Aeson® artificial heart is provided.

Trading of CARMAT shares suspended, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025

Paris, August 13, 2025 – 6:00 pm CEST    

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025.

Update on the ongoing receivership procedure

Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, the judiciary administrator had received, by the deadline of July 31, 2025, one takeover bid within the context of a sales plan (the “Bid”)[1].

This Bid will be assessed by the Versailles Economic Court[2] (the “Court”) at a hearing scheduled on August 19, 2025.

The Company again draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. The Company also reminds that even if the Bid is validated by the Court, the Company’s shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables. CARMAT is subject to a risk of liquidation, including in the short term.

Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR)

Ahead of the court hearing scheduled on August 19, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on August 14, 2025, before the stock market opens.

Another press release will be issued by the Company once the outcome of the court hearing is known.

In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart.

^[1] « Offre de reprise en plan de cession » (in French).

[2] Tribunal des Activités Economiques de Versailles.